Based on the provided data, the forecast for Renin-Angiotensin System medicine sales in Italy shows a gradual decline from 2024 to 2028, with sales expressed in percent of total sales. In 2023, the value stood at 4.8%. Comparing 2024 and 2023, the year-on-year variation shows a decline of 2.08%. Over the following years, from 2024 to 2025, the variation is -2.13%, and remains stable at 0% from 2025 to 2027, before declining by 2.17% from 2027 to 2028. The CAGR for the period from 2024 to 2028 indicates an average annual decline of approximately 1.07%.
Future trends to watch include the potential impact of new market entrants and innovative treatments for cardiovascular conditions, regulatory changes, and shifting patient preferences toward personalized medicine. These factors could influence the dynamics and competitive landscape of the Renin-Angiotensin System medicine market in Italy over the coming years.
